Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. on April 22, 2016. The filing addresses significant changes in corporate governance and executive leadership effective immediately on the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensatory arrangements rather than financial performance.
Material Changes
- Resignation: Dr. Raymond F. Akers, Jr., PhD, resigned as Executive Chairman and Co-Chairman of the Board.
- Continued Service: Dr. Akers will continue to serve as a director of the Company.
- Leadership Appointment: Thomas Knox, previously Co-Chairman, was appointed as the sole Chairman of the Board.
- New Role and Compensation: Dr. Akers was appointed as Co-Founder/Chief Scientific Director with an annual base salary of $200,000. He is also eligible for performance bonuses at the Board's sole discretion.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document is limited to the disclosure of the executive departure and subsequent appointments.
Investor Verification Checklist
- Verify the effective date of Dr. Akers' resignation and new appointment (April 22, 2016).
- Confirm the new compensation structure for Dr. Akers ($200,000 base salary plus discretionary bonuses).
- Review the Board composition to confirm Thomas Knox's status as sole Chairman.
- Check for any subsequent filings regarding the strategic impact of these leadership changes.